NDA 218145 · Otsuka
Simtriyo
Centanafadine Hydrochloride · Oral
NovelPriority reviewCDER novel approval, Jul 24, 2026: To treat attention-deficit hyperactivity disorder
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 24, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
25
12 Phase 3, 5 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL IDEATION AND BEHAVIORS IN PEDIATRIC PATIENTS AGED 6 YEARS AND OLDER; and ABUSE, MISUSE AND ADDICTION Suicidal Ideation and Behaviors in Pediatric Patients 6 Years of Age and Older In a short-term (6-week) clinical study, higher rates of suicidal ideation and behavior were reported in SIMTRIYO-treated pediatric patients with attention deficit/hyperactivity disorder (ADHD) aged 6 to 12 years than in pediatric patients treated with placebo. All pediatric patients 6 years of age or older treated with SIMTRIYO should be monitored closely for suicidal ideation and behaviors, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy. Families and caregivers should be advised of the need for close observation and communication with the healthcare provider. Consider stopping SIMTRIYO in patients who experience emergent suicidal ideation...
What it is approved for
From the label in effect Jul 31, 2026.
SIMTRIYO is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older weighing at least 20 kg. Limitations of Use The use of SIMTRIYO is not recommended in pediatric patients: Younger than 6 years of age because this pediatric subpopulation had a higher incidence of weight loss than pediatric patients 6 years of age and older [see Use in Specific Populations (8.4) ] . Weighing less than 20 kg because of a lack of data for this subpopulation and the risk of weight loss [see Use in Specific Populations (8.4) ] . SIMTRIYO is a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant indicated for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg. ( 1 ) Limitations of Use The use of SIMTRIYO is not recommended in pediatric patients: Younger than 6 years of age because this pediatric subpopulation had a higher incidence of weight loss than pediatric patients 6 years of age and older. ( 8.4 ) Weighing less than 20 kg because of a lack of data for this subpopulation and the risk of weight loss. ( 8.4 ).
Mechanism: Centanafadine has inhibitory activity at norepinephrine (NE), dopamine (DA), and serotonin (5-HT) reuptake transporters and is a central nervous system stimulant. The mechanism of action of centanafadine in the treatment of ADHD is unclear; however, its efficacy could be mediated through its activity as a norepinephrine-dopamine-serotonin reuptake inhibitor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 24, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
- SIMTRIYO · CENTANAFADINE HYDROCHLORIDE EQ 140MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- SIMTRIYO · CENTANAFADINE HYDROCHLORIDE EQ 210MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- SIMTRIYO · CENTANAFADINE HYDROCHLORIDE EQ 280MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Centanafadine" as an intervention, any sponsor and status, largest first.
- A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05279313 · 680 participants · Start Feb 24, 2022 · Primary completion Apr 24, 2026
Drug: Centanafadine Hydrochloride · For: Attention Deficit/Hyperactivity Disorder
Sites: Dothan, Alabama; Saraland, Alabama; Phoenix, Arizona · 86 sites in all
- A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03605849 · 662 participants · Start Feb 14, 2019 · Primary completion Sep 7, 2021
Drug: Centanafadine SR · For: Attention Deficit Disorder; Attention Deficit Hyperactivity Disorder
Sites: Culver City, California
- Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsPivotal-lookingRecruiting
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT06931080 · 630 participants (planned) · Start Apr 30, 2025 · Primary completion Dec 2027
Drug: EB-1020 (Centanafadine) 164.4 mg; EB-1020 (Centanafadine) 328.8 mg and 1 more · For: Attention Deficit Hyperactivity Disorder (ADHD)
Sites: Tokyo, Japan
- A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03605680 · 604 participants · Start Jan 16, 2019 · Primary completion Apr 11, 2020
Drug: Centanafadine SR; Centanafadine SR · For: Attention Deficit Disorder; Attention Deficit Hyperactivity Disorder
Sites: New York, New York
- A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03605836 · 590 participants · Start Jan 16, 2019 · Primary completion May 14, 2020
Drug: Centanafadine SR; Centanafadine SR · For: Attention Deficit Disorder; Attention Deficit Hyperactivity Disorder
Sites: Orlando, Florida
- A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05428033 · 574 participants · Start Jul 11, 2022 · Primary completion Mar 17, 2025
Drug: centanafadine capsule · For: Attention Deficit/Hyperactivity Disorder
Sites: New York, New York
- A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05257265 · 459 participants · Start Feb 2, 2022 · Primary completion Sep 29, 2023
Drug: Centanafadine Hydrochloride · For: Attention-Deficit/Hyperactivity Disorder
Sites: New York, New York
- Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05536414 · 337 participants · Start Sep 12, 2022 · Primary completion May 16, 2025
Drug: Centanafadine; Escitalopram and 1 more · For: Major Depressive Disorder
Sites: Yuma, Arizona; Bryant, Arkansas; Glendale, California · 62 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial.
Ward CL, Childress AC, Jin N, et al. · J Am Acad Child Adolesc Psychiatry 2026 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Centanafadine in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Muneer MA, Naveed M, Amjad M, et al. · Psychopharmacol Bull 2026 · Systematic Review, Meta-Analysis
- Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials.
Adler LA, Adams J, Madera-McDonough J, et al. · J Clin Psychopharmacol 2022 · Clinical Trial, Phase III, Multicenter Study
- A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy.
Schein J, Cloutier M, Gauthier-Loiselle M, et al. · J Comp Eff Res 2024 · Comparative Study, Randomized Controlled Trial
- Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Wilens TE, Oberdhan D, Jin N, et al. · J Child Adolesc Psychopharmacol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- A Randomized Thorough QT Trial Using Concentration-QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization.
Turkoglu OS, Wang X, Repella-Gordon J, et al. · Clin Pharmacol Drug Dev 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.